The first of these studies were performed with both hu14.18-IL2 and the anti-EpCAM IC, huKS-IL2, and showed that both agents induced target cell conjugation between NK cell lines lacking FcR but constitutively expressing CD25, and the tumor cell expressing the appropriate tumor target (GD2 or EPCAM, respectively) [86]. The gene discussed is IL2; the disease is neoplasm.